178 related articles for article (PubMed ID: 22383632)
41. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.
Witowski J; Korybalska K; Ksiazek K; Wisniewska-Elnur J; Jörres A; Lage C; Schaub TP; Passlick-Deetjen J; Breborowicz A; Grzegorzewska A; Ksiazek A; Liberek T; Lichodziejewska-Niemierko M; Majdan M; Rutkowski B; Stompór T; Sulowicz W
Nephrol Dial Transplant; 2004 Apr; 19(4):917-24. PubMed ID: 15031350
[TBL] [Abstract][Full Text] [Related]
42. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis.
Kawanishi K; Honda K; Tsukada M; Oda H; Nitta K
Perit Dial Int; 2013; 33(3):242-51. PubMed ID: 23123670
[TBL] [Abstract][Full Text] [Related]
43. Effect of neutral pH and low-glucose degradation product-containing peritoneal dialysis solution on residual renal function in peritoneal dialysis patients: a meta-analysis.
Wang J; Zhu N; Yuan W
Nephron; 2015; 129(3):155-63. PubMed ID: 25765060
[TBL] [Abstract][Full Text] [Related]
44. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
45. Effects of long-term treatment with low-GDP, pH-neutral solutions on peritoneal membranes in peritoneal dialysis patients.
Tawada M; Hamada C; Suzuki Y; Sakata F; Sun T; Kinashi H; Katsuno T; Takei Y; Maruyama S; Honda K; Mizuno M; Ito Y
Clin Exp Nephrol; 2019 May; 23(5):689-699. PubMed ID: 30547267
[TBL] [Abstract][Full Text] [Related]
46. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation.
Ha H; Yu MR; Choi HN; Cha MK; Kang HS; Kim MH; Lee HB
Perit Dial Int; 2000; 20 Suppl 5():S10-8. PubMed ID: 11229606
[TBL] [Abstract][Full Text] [Related]
47. No significant differences in peritoneal fluid handling in children using PH-neutral or acidic solutions.
Nourse P; van de Kar NC; Willems HL; Schröder CH
Perit Dial Int; 2006; 26(5):587-92. PubMed ID: 16973515
[TBL] [Abstract][Full Text] [Related]
48. Vasoactive components of dialysis solution.
Zakaria el R; Patel AA; Li N; Matheson PJ; Garrison RN
Perit Dial Int; 2008; 28(3):283-95. PubMed ID: 18474922
[TBL] [Abstract][Full Text] [Related]
49. Glucose degradation products and peritoneal membrane function.
Witowski J; Bender TO; Gahl GM; Frei U; Jörres A
Perit Dial Int; 2001; 21(2):201-5. PubMed ID: 11330569
[TBL] [Abstract][Full Text] [Related]
50. The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?
Perl J; Nessim SJ; Bargman JM
Kidney Int; 2011 Apr; 79(8):814-24. PubMed ID: 21248712
[TBL] [Abstract][Full Text] [Related]
51. Take care in how you store your PD fluids: actual temperature determines the balance between reactive and non-reactive GDPs.
Erixon M; Wieslander A; Lindén T; Carlsson O; Forsbäck G; Svensson E; Jönsson JA; Kjellstrand P
Perit Dial Int; 2005; 25(6):583-90. PubMed ID: 16411526
[TBL] [Abstract][Full Text] [Related]
52. Continuous flow peritoneal dialysis: solution formulation and biocompatibility.
Passlick-Deetjen J; Lage C; Jörres A
Semin Dial; 2001; 14(5):384-7. PubMed ID: 11679109
[TBL] [Abstract][Full Text] [Related]
53. Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH.
Zareie M; Keuning ED; ter Wee PM; Schalkwijk CG; Beelen RH; van den Born J
Nephrol Dial Transplant; 2006 Jan; 21(1):208-16. PubMed ID: 16263741
[TBL] [Abstract][Full Text] [Related]
54. GSK-3β inhibition protects mesothelial cells during experimental peritoneal dialysis through upregulation of the heat shock response.
Rusai K; Herzog R; Kuster L; Kratochwill K; Aufricht C
Cell Stress Chaperones; 2013 Sep; 18(5):569-79. PubMed ID: 23494401
[TBL] [Abstract][Full Text] [Related]
55. Associations of neutral pH, low-GDP peritoneal dialysis solutions with patient survival, transfer to haemodialysis and peritonitis.
Chen JHC; Johnson DW; Cho Y; Cheetham M; Sud K; Hayat A; Stallard B; Clayton P; Davies CE; Borlace M; Boudville N
Nephrol Dial Transplant; 2024 Jan; 39(2):222-232. PubMed ID: 37429598
[TBL] [Abstract][Full Text] [Related]
56. The effects of peritoneal dialysis solutions on peritoneal host defense.
Mortier S; Lameire NH; De Vriese AS
Perit Dial Int; 2004; 24(2):123-38. PubMed ID: 15119633
[TBL] [Abstract][Full Text] [Related]
57. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
Williams JD; Topley N; Craig KJ; Mackenzie RK; Pischetsrieder M; Lage C; Passlick-Deetjen J;
Kidney Int; 2004 Jul; 66(1):408-18. PubMed ID: 15200450
[TBL] [Abstract][Full Text] [Related]
58. Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve?
Chung SH; Stenvinkel P; Bergström J; Lindholm B
Perit Dial Int; 2000; 20 Suppl 5():S57-67. PubMed ID: 11229614
[TBL] [Abstract][Full Text] [Related]
59. The impact of dialysis solution biocompatibility on ultrafiltration and on free water transport in rats.
Aubertin G; Choquet P; Dheu C; Constantinesco A; Ratomponirina C; Zaloszyc A; Passlick-Deetjen J; Fischbach M
Pediatr Nephrol; 2012 Jan; 27(1):131-8. PubMed ID: 21744055
[TBL] [Abstract][Full Text] [Related]
60. Peritoneal equilibration test with conventional 'low pH/high glucose degradation product' or with biocompatible 'normal pH/low glucose degradation product' dialysates: does it matter?
Van Overmeire L; Goffin E; Krzesinski JM; Saint-Remy A; Bovy P; Cornet G; Bovy C
Nephrol Dial Transplant; 2013 Jul; 28(7):1946-51. PubMed ID: 23223220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
